Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy.
advantages
desmopressin
hemophilia A
patient perspective
side effects
survey
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
01
2023
revised:
22
05
2023
accepted:
01
06
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Desmopressin increases plasma factor VIII and von Willebrand factor levels in persons with nonsevere hemophilia A. Patients' perspectives on desmopressin are relevant to increase and optimize its suboptimal use. However, patients' views on desmopressin are not reported. To evaluate the perspectives of persons with nonsevere hemophilia A on desmopressin use, barriers for its use, side effects, and their knowledge about desmopressin's efficacy and side effects. Persons with nonsevere hemophilia A were included in a cross-sectional, national, multicenter study. Questionnaires were filled out by adult patients and children aged ≥12 years themselves. Caretakers filled out questionnaires for children aged <12 years. In total, 706 persons with nonsevere hemophilia A were included (544 mild, 162 moderate, [age range, 0-88 years]). Of 508 patients, 234 (50%) patients reported previous desmopressin use. Desmopressin was considered as at least moderately effective in 171 of 187 (90%) patients. Intranasal administration was the modality of choice for 138 of 182 (76%) patients. Flushing was the most reported side effect in 54 of 206 (26%) adults and 7 of 22 (32%) children. The most frequently reported advantage and disadvantage were the convenience of intranasal, out-of-hospital administration by 56% (126/227) and side effects in 18% (41/227), respectively. Patients' self-perceived knowledge was unsatisfactory or unknown in 28% (63/225). Overall, desmopressin was most often used intranasally and considered effective, with flushing as the most common side effect. The most mentioned advantage was the convenience of intranasal administration and disadvantage was side effects. More information and education on desmopressin could answer unmet needs in patients with current or future desmopressin treatment.
Sections du résumé
Background
UNASSIGNED
Desmopressin increases plasma factor VIII and von Willebrand factor levels in persons with nonsevere hemophilia A. Patients' perspectives on desmopressin are relevant to increase and optimize its suboptimal use. However, patients' views on desmopressin are not reported.
Objectives
UNASSIGNED
To evaluate the perspectives of persons with nonsevere hemophilia A on desmopressin use, barriers for its use, side effects, and their knowledge about desmopressin's efficacy and side effects.
Methods
UNASSIGNED
Persons with nonsevere hemophilia A were included in a cross-sectional, national, multicenter study. Questionnaires were filled out by adult patients and children aged ≥12 years themselves. Caretakers filled out questionnaires for children aged <12 years.
Results
UNASSIGNED
In total, 706 persons with nonsevere hemophilia A were included (544 mild, 162 moderate, [age range, 0-88 years]). Of 508 patients, 234 (50%) patients reported previous desmopressin use. Desmopressin was considered as at least moderately effective in 171 of 187 (90%) patients. Intranasal administration was the modality of choice for 138 of 182 (76%) patients. Flushing was the most reported side effect in 54 of 206 (26%) adults and 7 of 22 (32%) children. The most frequently reported advantage and disadvantage were the convenience of intranasal, out-of-hospital administration by 56% (126/227) and side effects in 18% (41/227), respectively. Patients' self-perceived knowledge was unsatisfactory or unknown in 28% (63/225).
Conclusion
UNASSIGNED
Overall, desmopressin was most often used intranasally and considered effective, with flushing as the most common side effect. The most mentioned advantage was the convenience of intranasal administration and disadvantage was side effects. More information and education on desmopressin could answer unmet needs in patients with current or future desmopressin treatment.
Identifiants
pubmed: 37601028
doi: 10.1016/j.rpth.2023.100281
pii: S2475-0379(23)00181-4
pmc: PMC10439392
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100281Informations de copyright
© 2023 The Authors.
Références
Blood. 2016 Oct 20;128(16):2007-2016
pubmed: 27587878
J Thromb Haemost. 2003 Apr;1(4):682-9
pubmed: 12871401
Haemophilia. 2017 Nov;23(6):861-867
pubmed: 28636264
Am J Hematol. 2007 Aug;82(8):731-5
pubmed: 17492648
Patient Educ Couns. 2004 Jun;53(3):285-90
pubmed: 15186865
Haemophilia. 2014 Mar;20(2):158-67
pubmed: 23937614
Haemophilia. 2017 Jan;23(1):82-88
pubmed: 27641050
Blood. 2014 Jun 12;123(24):3706-13
pubmed: 24705491
Blood. 2004 Dec 1;104(12):3494-500
pubmed: 15308570
Haemophilia. 2012 Mar;18(2):166-74
pubmed: 21771207
J Thromb Haemost. 2014 Jan;12(1):110-2
pubmed: 24406067
Blood. 2010 Jun 10;115(23):4902-9
pubmed: 20351306
Haemophilia. 2012 Sep;18(5):693-8
pubmed: 22458978
Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S1065-S1068
pubmed: 28803720
Haemophilia. 2018 Sep;24(5):720-725
pubmed: 30004154
J Thromb Haemost. 2015 Jul;13(7):1217-25
pubmed: 25912309
Semin Thromb Hemost. 2013 Oct;39(7):732-9
pubmed: 24030345
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Haemophilia. 2016 Jan;22(1):39-45
pubmed: 26036844
Res Pract Thromb Haemost. 2022 Aug 31;6(6):e12777
pubmed: 36090159
Blood. 2016 Jul 7;128(1):104-9
pubmed: 27207787
Haemophilia. 2013 Sep;19(5):720-6
pubmed: 23711294
J Thromb Haemost. 2014 Jan;12(1):36-42
pubmed: 24118899
Thromb Haemost. 1985 Aug 30;54(2):387-9
pubmed: 3936212
Haematologica. 2018 Mar;103(3):550-557
pubmed: 29305412
J Thromb Haemost. 2009 Nov;7(11):1824-31
pubmed: 19719828